Physiomics Plc (PYC) Fair Value & Analysis
Healthcare · GB · Market cap 3.2M GBX
Fair value as of: Jun 25, 2026
From 2 valuation models · updated 4 days ago
Share price −28.6% over the past month.
Price vs Fair Value (12 months)
12‑month range £0.0028 – £0.0074 · the £0.0053 price screens below the £0.0100 fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Physiomics Plc (PYC) currently trades at £0.0053, while our model-based Fair Value estimate is £0.0100 — implying the stock looks roughly 90.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Physiomics Plc generated revenue of £1.0M at a net margin of -48.1%. Revenue grew 49.2% year over year. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Physiomics Plc reported revenue of £784K in FY2025 versus £702K in FY2021, a compound +2.8%/yr. Reported net income was −£415K in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$607.20 | R$74.60 | -88% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Physiomics Plc (PYC) undervalued?
What is the fair value of PYC?
What is the quality score of PYC?
What is the revenue of Physiomics Plc (PYC)?
What is the net profit margin of PYC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.